AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (December 14, 2007). doi:10.1152/ajpheart.01200.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/2/H970    most recent
01200.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, S.
Right arrow Articles by Das, D. K.
Submitted on October 15, 2007
Accepted on December 10, 2007

CARDIOPROTECTION WITH PALM OIL TOCOTRIENOLS: COMPARISION OF DIFFERENT ISOMERS

Samarjit Das1, Istvan Lekli1, Manika Das1, Gergo Szabo2, Judit Varadi2, Bela Juhasz2, Istvan Bak2, Kalanithi Nesaretam3, Arpad Tosaki2, Saul R Powell4, and Dipak K. Das5*

1 Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, Connecticut, United States
2 Pharmacy, University of Debrecen, Debrecen, Hungary
3 Board, Malaysian Palm Oil Board, Kuala Lumpur, Malaysia
4 Medicine, Feinstein Institute for Medical research, New Hyde Park, New York, United States
5 Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, United States

* To whom correspondence should be addressed. E-mail: ddas{at}neuron.uchc.edu.

A recent study from our laboratory indicated the cardioprotective ability of tocotrienol rich factor (TRF) from the red palm oil. The present study compared cardioprotective abilities of different isomers of tocotrienols against TRF. The rats were randomly assigned to one of the five groups: The animals were given by gavaging either 3.5% of TRF or one of the isomers of tocotrienols, {alpha}, {gamma} or {delta} while the control animals were given (by gavaging) vehicle only. After 4 weeks, the rats were sacrificed and the hearts were then subjected to 30 min of global ischemia followed by 2 h of reperfusion. Dose-response and time-response studies revealed optimal concentration for TRF as 3.5% TRF and 0.3 mg/kg body wteight of tocotrienol isoforms given for 4 weeks. TRF as well as all the isomers of tocotrienol used in our study provided cardioprotection as evidenced by their ability to improve postischemic ventricular functions, improve electrical rhythm disturbances and to reduce myocardial infarct size. {gamma}-isoform tocotrienol was the most cardioprotective of all the isomers followed by {alpha}- and {delta}-. The molecular mechanisms of cardioprotection afforded by tocotrienols were probed by evaluating their respective abilities to stabilize proteasome allowing it to maintain a balance between pro-death and pro-survival signals. Our results demonstrated that tocotrienols diminished c-Src but increased phosphorylation of Akt thus generating a survival signal.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.